Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Abattis Bioceuticals Corp ATTBF

Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.


GREY:ATTBF - Post by User

Post by Maximumon Jan 28, 2019 2:29pm
191 Views
Post# 29289581

Rob the robber Robert Abenante, male, 34 years old

Rob the robber Robert Abenante, male, 34 years old
Case 1: The BCSC Executive Director is alleging a scheme where the consultant exemption was misused to sell shares without a prospectus, netting the firm millions of dollars. In total, four companies, sold over $17 million worth of shares to members of the BridgeMark Group, and then returned over $15 million to those same group members. They then sold those securities at a discount on the open market, generating over $6 million in profit for themselves. Amid speculation that BridgeMark Group completed similar transactions with seven other companies, the Executive Directors temporary order prohibits a total of eleven CSE-listed companies from using BridgeMark Group or other consultant exemptions to sell their shares. The list includes Liht Cannabis (CSE: LIHT) (OTCQX: LIHTF), BeLeave (CSE: BE) (OTCMTKS:BLEVF), Abattis (CSE:ATT) (OTC:ATTBF), Speakeasy Cannabis Club (CSE:EASY) (OTCMKTS: SPBBF), PreveCeutical (CSE:PREV) (OTC:PRVCF), and Affinor Growers (CSE:AFI) (OTCMKTS:RSSFF). Case 2: Blox Inc. has filed a lawsuit against its former president, Robert Abenante. The suit claims that he made unsubstantiated payments with company money, and failed in his role as president.
<< Previous
Bullboard Posts
Next >>